Arimidex/Faslodex/Iressa Study: A Phase II Trial of Primary Systemic Therapy Using a Combination of Arimidex, Faslodex and Iressa (Gefitinib) in Postmenopausal Women With Hormone Receptor Positive Breast Cancer

NCT00206414 Phase 2 TERMINATED

The investigators want to know if combining Arimidex and Faslodex with Iressa will be an effective treatment for breast cancer. They also want to know, using special tests on the tumor, the changes that occur with the treatment so they can try to improve their treatment for breast cancer in the future.

Details

Lead sponsor	Baylor Breast Care Center
Phase	Phase 2
Status	TERMINATED
Enrolment	15
Start date	2003-01
Completion	2006-09

Conditions

• BREAST CANCER

Interventions

• Iressa Day 1 given with Arimidex and Faslodex
• Iressa Day 21 given with Arimidex and Faslodex

Primary outcomes

• Primary study objective - To determine the clinical response rate of primary breast cancer to the combination of Arimidex, Faslodex, and Iressa — until disdase progression

Countries

United States